Home > Oncology > ESMO 2020 > Lung Cancer > Preoperative immunotherapy in early stage NSCLC safe and feasible

Preoperative immunotherapy in early stage NSCLC safe and feasible


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Conference
ESMO 2020
Both the phase 2 IONESCO and the phase 2 PRINCEPS trial evaluated adjuvant immunotherapy in patients with early-stage, resectable, non-small cell lung cancer (NSCLC). Neoadjuvant immunotherapy was shown to be feasible, safe, and not to delay or compromise surgery. In the IONESCO trial, 50 patients with early-stage NSCLC were included (IB ≥4 cm – IIIA, non N2). The patients were treated with 3 courses of durvalumab (750 mg, day 1, 15, 29). Surgery was scheduled between day 2 and 14 after the last infusion [1]. In the PRINCEPS trial, 30 patients were included (I > 2cm - IIIA, non N2). Patients received 1 injection of atezolizumab (1,200 mg). Surgery was scheduled in week 4 after the atezolizumab treatment [2]. In IONESCO, 46 patients received neoadjuvant treatment of whom 43 went into surgery without any delay. Overall, 41/46 patients in IONESCO (89.1%) had complete surgical resection (R0); 4 (8.7%) had partial radiological response (RECIST 1.1), ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on